CN106038677A - 营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 - Google Patents
营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 Download PDFInfo
- Publication number
- CN106038677A CN106038677A CN201610375889.0A CN201610375889A CN106038677A CN 106038677 A CN106038677 A CN 106038677A CN 201610375889 A CN201610375889 A CN 201610375889A CN 106038677 A CN106038677 A CN 106038677A
- Authority
- CN
- China
- Prior art keywords
- preparation
- blood
- blood glucose
- parts
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 42
- 210000004369 blood Anatomy 0.000 title claims abstract description 42
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 32
- 239000008103 glucose Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 230000036772 blood pressure Effects 0.000 title claims abstract description 14
- 210000000496 pancreas Anatomy 0.000 title claims abstract description 13
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 13
- 229940067606 lecithin Drugs 0.000 claims abstract description 13
- 239000000787 lecithin Substances 0.000 claims abstract description 13
- 235000010445 lecithin Nutrition 0.000 claims abstract description 13
- 239000011651 chromium Substances 0.000 claims abstract description 10
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 10
- 239000003549 soybean oil Substances 0.000 claims abstract description 10
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 9
- 241000241413 Propolis Species 0.000 claims abstract description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 8
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims abstract description 8
- 229940069949 propolis Drugs 0.000 claims abstract description 8
- 229940050168 zinc lactate Drugs 0.000 claims abstract description 8
- 235000000193 zinc lactate Nutrition 0.000 claims abstract description 8
- 239000011576 zinc lactate Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 13
- 230000033228 biological regulation Effects 0.000 claims description 10
- 235000011201 Ginkgo Nutrition 0.000 claims description 7
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000007901 soft capsule Substances 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 4
- 239000011812 mixed powder Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims 2
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 208000030159 metabolic disease Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 150000004665 fatty acids Chemical class 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 102000003960 Ligases Human genes 0.000 abstract 1
- 108090000364 Ligases Proteins 0.000 abstract 1
- 229940068052 ginkgo biloba extract Drugs 0.000 abstract 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 238000011160 research Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 241000218628 Ginkgo Species 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 241000033695 Sige Species 0.000 description 5
- 239000007902 hard capsule Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010040007 Sense of oppression Diseases 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000005961 cardioprotection Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 230000010503 organ complication Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及保健食品领域,具体地说是一种营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法,其特征在于各组分配比如下:蜂胶5‑50份,富铬酵母1‑15份,乳酸锌1‑15份,卵磷脂5‑40份,大豆油20‑80份,银杏叶提取物3‑40份,本发明经实验研究显示,能够显著的提高葡萄糖耐量,预防高血糖和糖尿病的发生,并可有效帮助早期糖尿病患者和葡萄糖耐量异常者降低血糖,改善各种自觉症状,抑制脂肪酸、甘油三酯合成酶,纠正自由基代谢紊乱,增加抗氧化酶活性,改善动脉粥样硬化,进而起到保护心脏和大脑的作用,具有无毒副作用、安全性高、能够有效降低血糖等显著地优点。
Description
技术领域
本发明涉及保健食品领域,具体地说是一种营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法。
背景技术
众所周知,糖尿病是由遗传和环境因素相互作用而引起的一种代谢异常综合症。因胰岛素分泌、胰岛素作用或者两者同时存在缺陷,引起碳水化合物、蛋白质、脂肪、水和电解质等的代谢紊乱,临床症状以长期高血糖为主要特征。糖尿病可以引起多个器官的慢性并发症,进而导致人体器官功能障碍和衰竭,成为致残、致死的主要原因。
随着生活水平的提高,糖尿病患者人数逐渐增加,据统计全球糖尿病患者约1.32亿,我国有2000-3000万之多,由于糖尿病的病因和发病机制尚未完全明了,因此目前还缺乏有效的病因治疗方法,现阶段临床上对糖尿病的治疗多采用胰岛素注射治疗或者口服降糖药物治疗,然而由于治疗过程中需要长期用药,胰岛素注射治疗给患者带来许多不便,而口服降糖药物治疗中所采用的降糖药物多为化学药品或者生物药品,对人体有一定的副作用,长期服用,对病患身体健康会造成损害,因此,急需一种安全、有效、适于长期服用的降血糖保健食品。
发明内容
本发明中针对现有技术中存在的不足,提出一种能够营养胰岛、降低血糖、调节血压、血脂的降血糖的保健食品及其制备方法。
一种营养胰岛、降低血糖、调节血压血脂的制剂,其特征在于各组分配比如下:
蜂胶 5-50 份,富铬酵母 1-15 份,乳酸锌 1-15份,卵磷脂 5-40份,大豆油 20-80份,银杏叶提取物 3-40份。
本发明可以软胶囊、硬胶囊、片剂、颗粒剂、口服液等剂型。
一种营养胰岛、降低血糖、调节血压血脂的制剂的制备方法,其特征在于包括如下步骤:
步骤A:按配比取用蜂胶粉、银杏叶提取物、富铬酵母和乳酸锌,并将其混合均匀,制得混合粉,
步骤B:取大豆油20-80份,缓慢加热,至70℃,
步骤C:向步骤B中的大豆油内加入5-40份卵磷脂,缓慢搅拌,制得卵磷脂油液,
步骤D:向卵磷脂油液中加入步骤A中所得的混合粉,搅拌,使其混合均匀,
步骤E:将步骤D中制得的混合物进行消毒,制得具有降血糖作用的保健食品。
本发明将步骤E中所得的混合物装入软胶囊中即得软胶囊制剂。
本发明中将步骤E中所得的混合物烘干,制得混合物粉末,将该混合物粉末装入明胶硬胶囊中,即得硬胶囊制剂。
本发明还可以将步骤E中所得的混合物加工成片剂或者口服液制剂,以满足患者服用需求。
本发明经实验研究显示,能够显著的提高葡萄糖耐量,预防高血糖和糖尿病的发生,并可有效帮助早期糖尿病患者和葡萄糖耐量异常者降低血糖,改善各种自觉症状,抑制脂肪酸、甘油三酯合成酶,纠正自由基代谢紊乱,增加抗氧化酶活性,改善动脉粥样硬化,进而起到保护心脏和大脑的作用,具有无毒副作用、安全性高、能够有效降低血糖等显著地优点。
具体实施方式
一种营养胰岛、降低血糖、调节血压血脂的制剂,其特征在于各组分配比如下:
蜂胶 5-50 份,富铬酵母 1-15 份,乳酸锌 1-15份,卵磷脂 5-40份,大豆油 20-80份,银杏叶提取物 3-40份。
本发明中的蜂胶能够降低血糖、血脂以及过高的血压,并能够消除炎症,治疗感染,预防和治疗感染并发症,进而消除“三多一少”的症状,有效降低甘油三酯的含量,改善血管的弹性和渗透性,舒张血管,清除血管内壁的积存物,减少过氧化脂质对血管的危害,有效防止血管硬化。
本发明中银杏叶提取物中含有黄酮类化合物,通过增加胰岛β细胞分泌胰岛素,来达到调节血糖、血脂的目的,能够有效地改善高血压患者血液高凝状态以及血液的流变性。
本发明中卵磷脂能改善胰脏的功能,提高胰岛素的分泌水平,有效地将血液中的葡萄糖运送到细胞中,特别是对糖尿病坏疽及动脉硬化等并发症患者更为有效。同时卵磷脂还有乳化、分解油脂的作用,可促进血液循环,改善血清脂质,清除过氧化物,使血液中胆固醇及中性脂肪含量降低,减少脂肪在血管内壁的滞留时间,促进粥样硬化斑的消散,防止由胆固醇引起血管内膜损伤,保持血循环的畅通无阻。服用卵磷脂对高血脂和高胆固醇有显著疗效,因而可预防和治疗动脉硬化。
本发明中的富铬酵母以及乳酸锌,通过添加微量元素铬(Cr)和锌(Zn)对糖尿病患者糖、脂代谢的紊乱能够起到一定程度的改善,同时可以恢复血管壁弹性,有效预防动脉粥样硬化,减轻胰岛的病理损伤。
一种营养胰岛、降低血糖、调节血压血脂的制剂的制备方法,其特征在于包括如下步骤:
步骤A:按配比取用蜂胶粉、银杏叶提取物、富铬酵母和乳酸锌,并将其混合均匀,制得混合粉,
步骤B:取大豆油20-80份,缓慢加热,至70℃,
步骤C:向步骤B中的大豆油内加入5-40份卵磷脂,缓慢搅拌,制得卵磷脂油液,
步骤D:向卵磷脂油液中加入步骤A中所得的混合粉,搅拌,使其混合均匀,
步骤E:将步骤D中制得的混合物进行消毒,制得具有降血糖作用的保健食品。
本发明将步骤E中所得的混合物装入软胶囊中即得软胶囊制剂。
本发明中将步骤E中所得的混合物烘干,制得混合物粉末,将该混合物粉末装入明胶硬胶囊中,即得硬胶囊制剂。
本发明还可以将步骤E中所得的混合物加工成片剂或者口服液制剂,以满足患者服用需求。
下面结合临床病例对本发明做进一步的说明:
陈家良,男,51岁,半年前开始排尿困难、尿不尽、残余尿增多,有时还尿失禁尿脏内裤,小腹胀痛不适。还出现了不同程度吞咽困难,胃部不舒服,有时便秘,食欲差。经常空腹10.0,有时更高。三个月前,开始加服本品,吃了将近两个月时,血糖空腹降到7.0,排尿困难减轻,尿失禁的毛病得到改善,夜尿次数减少,也不再便秘。当然,食欲因这些善的改善也有明显增加。
秦素贞,女,55岁,1988年被诊断为非胰岛素依赖型(即II型)糖尿病,13年来,血糖(饭后2小时)一直在18.1~25之间不稳,24小时尿糖经常在7.8 ~8.1之间,同时有头晕耳鸣的症状,下肢经常浮肿,一天天什么事也不干还是筋疲力尽的样子;比别人格外的怕冷,面孔黄黄的,身体也虚胖了好多,看起好骇人。要命的是夜间起尿三四次,还常拉肚子,血脂高(胆固醇总量10~15,甘油三脂4~5),整天觉也睡不好,一睡下就做梦。今年一进夏天,儿子坚持让她服用本品,约摸有一个多月,头不晕了,精神明显好转。两个月后,身上的各种并发症见轻很多,血糖6.0,24小时尿糖2.2。目前的情况很稳定,还在继续服用。
李碧芳,女,65岁从2001年6月自觉气短、乏力、没有精神,喜欢多喝水,喝水后又感觉不能解渴,食欲好,然而肥胖的体重却从那时明显消瘦。因家族有糖尿病史,就疑心自己是患上了糖尿病。到医院去做血糖检测,果然,空腹血糖8.2,餐后2小时血糖10.3,尿糖两个加号。两个月前的一天早上,她看到本品,治糖尿病及其并发症,决心试一试。服用35天左右,血糖逐渐恢复正常,尿糖由两个加号变成一个加号,45天后尿糖由加号到减号,体力恢复,夜尿由4次变成1次,睡眠好,体重逐渐上升。目前,仍旧不间断地服用本品,血糖控制满意,并发症也没再出来“兴风作浪”。
李茹琴,女,54岁过完2001年的春节,被诊断为患了Ⅱ型糖尿病,伴发周围神经炎。得了这病,需要终生服药和病情赛跑,于是从那时就开始服用降糖药,如降糖灵、美迪康等,但效果不是很理想,餐后2小时血糖9.1,空腹血糖徘徊在8.0,尿糖在一个加号和两个加号之间。平常食欲还行,但就是经常失眠,浑身乏力,胸闷气短,夜里起尿三四次,两条腿经常浮肿。两年前皮肤有灼烧一样的疼痛,四肢有麻木感,血压也很高,收缩压升高到180,舒张压110,尿检蛋白三个加号。不过,现在她的罪快受到头了,一糖尿病病友向她推荐了本品。服用不超过一个月时,皮肤灼痛的感觉减轻,四肢窜痛和麻木得了到很大的改善。吃到第38天,发觉下肢浮肿明显好转,尿蛋白由三个加号变为一个加号,血压回落到130到90。睡眠得到很大改善,精神变好了,胸闷气短的情况基本消失。测了一下,血糖下降为空腹5.5,餐后2小时7.5,24小时尿糖6.2 。两个多月过去了,情况开始稳定,
史克明,男,42岁,经商患Ⅱ型糖尿病6年,血糖经常偏高,空腹血糖大于13.0 ,餐后2小时血糖大于15.2,尿糖在三个加号和四个加号之间,平时肝功能也不好。因为食欲旺盛,身体比较肥胖(体重95公斤,身高1.78米)。正当她为自己的病感到“山重水复疑无路”,没想到本品的出现却让她“柳暗花明又一村”。她服用本品27日后,体力明显好转。由于本品治疗并发症的功能十分卓著,服用三个多月,肝功开始正常,澳抗转阴,血糖控制在正常人水平,肝区不适消失。现在精神好,6点起床至晚上11点休息,在高度紧张的工作中依然保持着健康的状态。
本发明经实验研究显示,能够显著的提高葡萄糖耐量,预防高血糖和糖尿病的发生,并可有效帮助早期糖尿病患者和葡萄糖耐量异常者降低血糖,改善各种自觉症状,抑制脂肪酸、甘油三酯合成酶,纠正自由基代谢紊乱,增加抗氧化酶活性,改善动脉粥样硬化,进而起到保护心脏和大脑的作用,具有无毒副作用、安全性高、能够有效降低血糖等显著地优点。
Claims (3)
1.一种营养胰岛、降低血糖、调节血压血脂的制剂,其特征在于各组分配比如下:
蜂胶 5-50 份,富铬酵母 1-15 份,乳酸锌 1-15份,卵磷脂 5-40份,大豆油 20-80份,银杏叶提取物 3-40份。
2.一种营养胰岛、降低血糖、调节血压血脂的制剂的制备方法,其特征在于包括如下步骤:
步骤A:按配比取用蜂胶粉、银杏叶提取物、富铬酵母和乳酸锌,并将其混合均匀,制得混合粉,
步骤B:取大豆油20-80份,缓慢加热,至70℃,
步骤C:向步骤B中的大豆油内加入5-40份卵磷脂,缓慢搅拌,制得卵磷脂油液,
步骤D:向卵磷脂油液中加入步骤A中所得的混合粉,搅拌,使其混合均匀,
步骤E:将步骤D中制得的混合物进行消毒,制得具有降血糖作用的保健食品。
3.根据权利要求2所述的一种营养胰岛、降低血糖、调节血压血脂的制剂的制备方法,其特征在于将步骤E中所得的混合物装入软胶囊中,制得软胶囊制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610375889.0A CN106038677A (zh) | 2016-05-31 | 2016-05-31 | 营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610375889.0A CN106038677A (zh) | 2016-05-31 | 2016-05-31 | 营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106038677A true CN106038677A (zh) | 2016-10-26 |
Family
ID=57173199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610375889.0A Pending CN106038677A (zh) | 2016-05-31 | 2016-05-31 | 营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106038677A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101890060A (zh) * | 2010-07-09 | 2010-11-24 | 威海康宝生物科技开发有限公司 | 营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 |
-
2016
- 2016-05-31 CN CN201610375889.0A patent/CN106038677A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101890060A (zh) * | 2010-07-09 | 2010-11-24 | 威海康宝生物科技开发有限公司 | 营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
樊蔚虹: "《高血脂饮食养生宝典》", 31 May 2013, 西安:陕西科学技术出版社 * |
焦学瞬: "《表面活性剂实用新技术》", 30 September 1993, 北京:中国轻工业出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100374140C (zh) | 一种用于糖尿病的保健品 | |
CN106038704A (zh) | 一种用于抑制食物消化吸收的组合物、制备方法及用途 | |
CN101890060B (zh) | 营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 | |
CN108295211A (zh) | 一种治疗糖尿病的药食同源食品组方及其制备方法 | |
CN102526479A (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN102935116A (zh) | 一种具有降血糖功效的药物组合物或保健品 | |
CN103719864A (zh) | 一种降血糖纳豆组合胶囊及其制备方法 | |
CN106421581A (zh) | 一种用于治疗糖尿病的生物中药内服药及其制备方法 | |
CN102614359B (zh) | 一种治疗糖尿病的中药制剂及制备方法 | |
CN102406711A (zh) | 一种治疗糖尿病的药物 | |
JP2019210269A (ja) | 糖尿疾患の治療用組成物 | |
CN101406642B (zh) | 一种降糖的复方制剂 | |
CN106038677A (zh) | 营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 | |
CN102114185B (zh) | 一种治疗2型糖尿病胰岛素抵抗的药物 | |
CN105733880A (zh) | 一种以榛子粕为原料酿制的复合榛子酒 | |
CN103181945B (zh) | 丝瓜子的用途 | |
CN104984331A (zh) | 生物活性多酶修复胰腺β细胞溶液制剂及其制备方法 | |
CN105663772B (zh) | 一种治疗糖尿病的药物 | |
CN101554396A (zh) | 一种治疗糖尿病和高血脂的中药 | |
CN115669935A (zh) | 营养胰岛、降低血糖、调节血压血脂的制剂及其制备方法 | |
CN115779046B (zh) | 一种防治糖尿病的中药组合物、中药制剂与应用 | |
CN109010621A (zh) | 一种治疗糖尿病的中药组合物、制备方法及其应用 | |
CN107335052A (zh) | 用于治疗糖尿病的配方产品 | |
CN102198174A (zh) | 滋肾清肝降糖调脂中药配方制剂及其制备方法 | |
US10561167B2 (en) | Hypoglycemic composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161026 |
|
WD01 | Invention patent application deemed withdrawn after publication |